Findell Capital Management LLC Acquires 8,000 Shares of Abivax SA Sponsored ADR $ABVX

Findell Capital Management LLC grew its position in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) by 20.0% in the fourth quarter, Holdings Channel reports. The fund owned 48,000 shares of the company’s stock after buying an additional 8,000 shares during the quarter. Abivax makes up about 1.9% of Findell Capital Management LLC’s portfolio, making the stock its 11th biggest position. Findell Capital Management LLC’s holdings in Abivax were worth $6,473,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. WPG Advisers LLC boosted its position in shares of Abivax by 125.9% during the 4th quarter. WPG Advisers LLC now owns 454 shares of the company’s stock valued at $61,000 after acquiring an additional 253 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its position in shares of Abivax by 661.5% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock valued at $53,000 after acquiring an additional 344 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Abivax by 4,612.5% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after acquiring an additional 369 shares during the last quarter. T. Rowe Price Investment Management Inc. bought a new position in shares of Abivax during the 4th quarter valued at approximately $61,000. Finally, Union Bancaire Privee UBP SA bought a new position in shares of Abivax during the 4th quarter valued at approximately $67,000. 47.91% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on ABVX. Citizens Jmp increased their target price on Abivax from $131.00 to $187.00 and gave the company a “market outperform” rating in a research report on Tuesday, June 2nd. Barclays increased their target price on Abivax from $142.00 to $148.00 and gave the company an “overweight” rating in a research report on Tuesday, March 24th. Oddo Bhf reiterated an “outperform” rating on shares of Abivax in a research report on Thursday, April 9th. Citigroup reiterated an “outperform” rating on shares of Abivax in a research report on Tuesday, June 2nd. Finally, BTIG Research reiterated a “buy” rating and set a $150.00 target price on shares of Abivax in a research report on Tuesday. Twelve equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $130.08.

Abivax Stock Performance

NASDAQ:ABVX opened at $100.15 on Thursday. The stock’s fifty day moving average is $114.81 and its 200 day moving average is $118.49. Abivax SA Sponsored ADR has a fifty-two week low of $5.69 and a fifty-two week high of $148.83. The firm has a market capitalization of $7.99 billion, a PE ratio of -19.22 and a beta of 0.69.

Abivax (NASDAQ:ABVX) last released its quarterly earnings results on Friday, May 22nd. The company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.94) by $0.23. The company had revenue of $1.56 million for the quarter, compared to analysts’ expectations of $0.40 million. Equities analysts forecast that Abivax SA Sponsored ADR will post -3.4 EPS for the current year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.